- Report
- August 2025
- 124 Pages
Global
From €3577EUR$3,999USD£3,097GBP
- Report
- January 2026
- 181 Pages
Global
From €3171EUR$3,545USD£2,745GBP
€3524EUR$3,939USD£3,051GBP
- Report
- February 2026
- 250 Pages
Global
From €4016EUR$4,490USD£3,477GBP
- Report
- April 2025
- 200 Pages
Global
From €2227EUR$2,490USD£1,928GBP
- Report
- February 2026
- 250 Pages
Global
From €4016EUR$4,490USD£3,477GBP
- Report
- December 2025
- 142 Pages
Global
From €4339EUR$4,850USD£3,756GBP
- Report
- September 2023
- 180 Pages
Global
From €5323EUR$5,950USD£4,608GBP
- Report
- June 2024
- 200 Pages
Global
From €7112EUR$7,950USD£6,157GBP
- Report
- June 2022
- 320 Pages
Global
From €12434EUR$13,900USD£10,765GBP
- Report
- January 2024
- 206 Pages
Global
From €3981EUR$4,450USD£3,446GBP
- Report
- June 2023
- 280 Pages
Global
From €2236EUR$2,500USD£1,936GBP

Choroidal Neovascularization (CNV) is a condition in which abnormal blood vessels grow beneath the retina in the eye. It is a major cause of vision loss in age-related macular degeneration (AMD). Optical treatments for CNV include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to destroy the abnormal blood vessels and prevent further vision loss. Photodynamic therapy uses a light-activated drug to destroy the abnormal vessels. Anti-VEGF injections are used to block the growth of new vessels and reduce fluid leakage.
The CNV market is highly competitive, with a number of companies offering treatments and products. These include Novartis, Regeneron, Allergan, Roche, Bayer, and Santen Pharmaceuticals. Show Less Read more